Serafin Labs, Inc. filed a Form D with the Securities and Exchange Commission on 2026-01-14.
Serafin Labs, Inc. filed a Form D notice of an exempt securities offering with the SEC on January 14, 2026. The filing reports $50K sold. Its industry group is Biotechnology. It names Sural Ranamukhaarachchi (Executive Officer, Director, Promoter), Daya Ranamukhaarachchi (Director), Stephanie Fraley (Director) (SEC Form D, January 14, 2026).
125 companies raised this week.
Companies that just raised money, and the people to call. Before you unlock: the company, the amount, the date and what is inside (for example 2 people, phone, LinkedIn). After: the officers and directors the filing names with their roles, how to reach the company, and a person's email only when we found one.
| Andersen Aggregator LLC | $1.9B | Business services |
| AT Umbrella LLC | $1.9B | Business services |
| Legora, Inc. | $221M | AI and software |
| MD INVESTMENT LLC | $169M | Business services |
| Serval Inc. | $149M | AI and software |
Is this your company?
Sell to companies like Serafin Labs, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
New Form D on file · 2026-01-14 · the record
Pitching, partnering or investing alongside them? See who really runs and owns Serafin Labs, Inc.
Free to see. No signup.
More on the people and the money behind Serafin Labs, Inc., from the filings we hold.
Biotechnology raises by companies based in California, filed in January 2026, largest first.
Get an email when Serafin Labs, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
We'll show it in your MentionFox inbox when Serafin Labs, Inc. raises, hires or launches. No email unless you switch it on.
Watch Serafin Labs, Inc. →Get the full cited report on Serafin Labs, Inc.
What the filing shows about Serafin Labs, Inc.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Serafin Labs, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
The filing gives Serafin Labs, Inc.'s address as 3971 Lamont Street, San Diego, CA 92109.
Saved here on this device in the meantime, so nothing is lost either way.
This is the company's own disclosure. A payment disclosed on a Form D is a disclosed use of proceeds, not a finding of wrongdoing.
Serafin Labs, Inc. is a registered filer with the SEC (CIK 2104899) and has filed since 2026-01-14. 1 filing is on record, the latest on 2026-01-14.
A filing shows the company exists and what it reports about itself. It is not an audit or a rating.
Serafin Labs, Inc.'s Form D of 2026-01-14 names Sural Ranamukhaarachchi, Daya Ranamukhaarachchi and Stephanie Fraley as its officers, directors or promoters.
Its new offerings report $50K sold across 1 offering, as its own filings state.
Trailing twelve months. 759 filings in Biotechnology, totalled by week. The dot is this raise, $50K, on the same scale — one filing against the whole group's total, so it sits low by construction.
Sural Ranamukhaarachchi is named as Executive Officer and Director and Promoter on the Form D that Serafin Labs, Inc. filed with the SEC on 14 January 2026, one of 3 people that filing names.
Daya Ranamukhaarachchi is named as Director on the Form D that Serafin Labs, Inc. filed with the SEC on 14 January 2026, one of 3 people that filing names.
Stephanie Fraley is named as Director on the Form D that Serafin Labs, Inc. filed with the SEC on 14 January 2026, one of 3 people that filing names.
3 people named on the filing — 1 holding an executive role and 2 as directors only.
Named as of the 2026-01-14 filing. Titles and locations are exactly as the filing states — not independently confirmed elsewhere.
No investor is drawn from a Form D — the form states how many invested and never who.
What the filing shows about Serafin Labs, Inc.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Serafin Labs, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Serafin Labs, Inc. covers
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
You land back on this company when you are in.
Not ready to upgrade? Keep this one in view instead.
Watchlist Serafin Labs, Inc.You get an alert in MentionFox the next time this company shows up.
If you're behind Serafin Labs, Inc.: the weeks after a raise are watched the same way — by other investors sizing you up, and by founders checking who just got funded. FoxPlug turns your commits, deploys, and releases into that story automatically. GetFoxChat puts a guide on your own site so the people this filing just sent you don't leave after one page.
Sourced from the filing index on sec.gov.
Each opens in a new tab, filled in for Serafin Labs, Inc.. With no account yet, you sign up free and land on the result.
On these lists: Biotech raises in San Diego
Share your raise. This card is drawn from the company's own Form D filing, and sharing needs no account.
https://mentionfox.com/funding/serafin-labs-inc-form-d-26000001